X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA GSK PHARMA SHASUN PHARMA/
GSK PHARMA
 
P/E (TTM) x 123.9 63.0 196.7% View Chart
P/BV x 8.5 10.1 84.3% View Chart
Dividend Yield % 0.2 1.3 18.6%  

Financials

 SHASUN PHARMA   GSK PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
GSK PHARMA
Mar-17
SHASUN PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs943,838 2.5%   
Low Rs462,637 1.7%   
Sales per share (Unadj.) Rs214.2354.2 60.5%  
Earnings per share (Unadj.) Rs5.339.8 13.4%  
Cash flow per share (Unadj.) Rs15.842.9 36.9%  
Dividends per share (Unadj.) Rs1.0030.00 3.3%  
Dividend yield (eoy) %1.40.9 154.4%  
Book value per share (Unadj.) Rs53.3236.9 22.5%  
Shares outstanding (eoy) m56.6284.70 66.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.39.1 3.6%   
Avg P/E ratio x13.181.4 16.1%  
P/CF ratio (eoy) x4.475.5 5.9%  
Price / Book Value ratio x1.313.7 9.6%  
Dividend payout %18.775.4 24.8%   
Avg Mkt Cap Rs m3,958274,216 1.4%   
No. of employees `000NA4.7 0.0%   
Total wages/salary Rs m2,1644,830 44.8%   
Avg. sales/employee Rs ThNM6,387.0-  
Avg. wages/employee Rs ThNM1,028.3-  
Avg. net profit/employee Rs ThNM717.1-  
INCOME DATA
Net Sales Rs m12,12730,000 40.4%  
Other income Rs m229728 31.5%   
Total revenues Rs m12,35630,728 40.2%   
Gross profit Rs m1,0094,190 24.1%  
Depreciation Rs m594263 225.7%   
Interest Rs m4150-   
Profit before tax Rs m2304,655 4.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m-731,744 -4.2%   
Profit after tax Rs m3023,368 9.0%  
Gross profit margin %8.314.0 59.6%  
Effective tax rate %-31.737.5 -84.5%   
Net profit margin %2.511.2 22.2%  
BALANCE SHEET DATA
Current assets Rs m6,88416,742 41.1%   
Current liabilities Rs m8,4567,202 117.4%   
Net working cap to sales %-13.031.8 -40.8%  
Current ratio x0.82.3 35.0%  
Inventory Days Days6252 119.0%  
Debtors Days Days10821 517.5%  
Net fixed assets Rs m4,9708,635 57.6%   
Share capital Rs m113847 13.4%   
"Free" reserves Rs m2,87519,222 15.0%   
Net worth Rs m3,02020,069 15.0%   
Long term debt Rs m1,81710 18,174.0%   
Total assets Rs m13,34730,038 44.4%  
Interest coverage x1.6NM-  
Debt to equity ratio x0.60 120,762.2%  
Sales to assets ratio x0.91.0 91.0%   
Return on assets %5.411.2 47.9%  
Return on equity %10.016.8 59.6%  
Return on capital %13.325.5 52.3%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,843528 1,106.6%   
Fx outflow Rs m2,1737,193 30.2%   
Net fx Rs m3,669-6,665 -55.1%   
CASH FLOW
From Operations Rs m3982,360 16.8%  
From Investments Rs m-1,6353,008 -54.4%  
From Financial Activity Rs m1,309-5,108 -25.6%  
Net Cashflow Rs m71260 27.4%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 3.6 10.2 35.3%  
FIIs % 17.6 23.8 73.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 15.4 257.1%  
Shareholders   20,750 102,036 20.3%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Continues Momentum; Metal Sector Up 2.5%(11:30 am)

After opening the day on a positive note, stock markets in India have continued their momentum. Sectoral indices are trading on a positive note with stocks in the metal sector.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS